# NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

> **NCT04540406** · PHASE2 · COMPLETED · sponsor: **Notitia Biotechnologies Company** · enrollment: 42 (actual)

## Conditions studied

- Suspected or Confirmed COVID-19

## Interventions

- **DRUG:** NBT-NM108
- **OTHER:** Usual Care Only

## Key facts

- **NCT ID:** NCT04540406
- **Lead sponsor:** Notitia Biotechnologies Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-02
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-03-14
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540406, "NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04540406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*